Hyperinsulinemic Euglycemic Clamp Protocol

Hyperinsulinemic Euglycemic Clamp Protocol
This study is not yet open for participant recruitment.
Verified on September 2011 by Torrent Pharmaceuticals Limited

First Received on July 29, 2011.  
Last Updated on September 14, 2011  
History of Changes
Sponsor: Torrent Pharmaceuticals Limited
Information provided by (Responsible Party): Torrent Pharmaceuticals Limited
ClinicalTrials.gov Identifier: NCT01408667

The purpose of the study is to determine the safety and efficacy of TRC150094 in male patients with cardiometabolic risk. Cardiometabolic risk which is the overall risk of cardiovascular disease (CVD) and diabetes resulting from the presence of hypertension, HDL cholesterol, insulin resistance, dysglycemia and visceral obesity.

Condition Intervention Phase
Metabolic Cardiovascular Syndrome Drug: TRC150094
Other: Placebo
Phase I
Phase II

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2A, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety and Efficacy of TRC150094 in Increasing Insulin Sensitivity in Male Patients With Increased Cardiometabolic Risk

Resource links provided by NLM:

Further study details as provided by Torrent Pharmaceuticals Limited:

Primary Outcome Measures:

  • The safety of TRC150094 once daily dosing for 4 weeks in male patients with increased cardiometabolic risk will be determined. [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]
    Safety parameters will include haematology, safety biochemistry, vital signs, ECG and AE check.

  • The efficacy (in increasing insulin sensitivity) of TRC150094 once daily dosing for 4 weeks in male patients with increased cardiometabolic risk will be determined. [ Time Frame: 1 month ] [ Designated as safety issue: No ]

    Efficacy assessment will include Insulin Sensitivity to be determined by:

    Rate of Glucose Disposal Suppression of Endogenous Glucose Production Suppression of rate of lipolysis

Secondary Outcome Measures:

  • The effect of TRC150094 on hepatic fat and metabolic parameters will be evaluated. [ Time Frame: 1 month ] [ Designated as safety issue: No ]

    Early efficacy markers to be explored includes:

    • Hepatic fat by magnetic resonance spectroscopy
    • Lipid parameters
    • Metabolic markers such as adiponectin, IL-6, TNF-alpha, CRP, glucagon, leptin etc.

  • The ethnic differences for effect of TRC150094 on Insulin sensitivity parameters will be evaluated. [ Time Frame: 1 month ] [ Designated as safety issue: No ]
    Difference in insulin sensitivity parameters (rate of glucose disposal) between caucasian and Indian populations.

Estimated Enrollment: 40
Study Start Date: October 2011
Estimated Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)


Assigned Interventions
Placebo: Placebo Comparator

Intervention: Other: Placebo
Other: Placebo

Tablets once daily
TRC150094: Active Comparator

Intervention: Drug: TRC150094
Drug: TRC150094

50 mg Tablets once a day

Detailed Description:

20 Subjects will be enrolled in Veeda Clinical research,India and another 20 subjects at Amsterdam, the Netherlands. The maximum duration of participation in the study for each subject will be 9.5 weeks including a less than or equal to 4 weeks screening period, 4 weeks of treatment and a 10 days post treatment follow-up evaluation period.

At each study site, 20 subjects will be enrolled. Each subject will attend the study centre in a fasting state, for a screening visit, 2 study visits (one baseline and one end of treatment), 1 intermediate safety visit and 1 post-study follow-up visit (Total 5 visits). The subjects at each site will be randomized to receive TRC150094 or placebo in a ratio of 1:1. 50 mg dose will be administered once daily (morning) under fasting conditions. Dosing will take place daily on Days 1-28. Subjects will arrive at the study centre for screening visit. Physical examination, vital signs, safety biochemistry and laboratory investigations for verification of inclusion/ exclusion criteria will be performed during screening visit. Subjects meeting all the inclusion criteria and none of the exclusion criteria and who have given their informed consent for the study will be asked to come for the study on Day 0 (or day -1 if required). Baseline investigations (including baseline clamp procedure and hepatic MRS) will be done on Day 0 (or day -1). Subjects will receive properly labelled bottle containing either Active treatment or Placebo as per the randomization number of the subject.


Ages Eligible for Study:   30 Years to 65 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects will be considered eligible for entry in the study if they meet all of the following criteria.

    1. Adult male
    2. Age range 30-65 years at screening
    3. Caucasian or Indian ethnicity
    4. Waist circumference ≥ 102 cm for Caucasians and ≥ 90 cm for Indians at screening.
    5. Fasting Serum Insulin ≥ 10 mU/ml at screening
    6. Blood Pressure ≥ 130/85 mmHg at screening (or patients taking medication for hypertension)
    7. Stable weight during 3 months prior to the study (assessed through medical history of the patient)
    8. Drug naive diabetic patients* or patients with impaired fasting glucose i.e > 100 mg/dl or 5.5 mmol/l and < 200 mg/dl or 11.0 mmol/l Diabetic patients who were taking metformin and have undergone washout for at least 4 weeks before Day 0 and are currently on life style modification as a treatment for diabetes will also be allowed in the study
    9. Willingness to give written informed consent (prior to any study-related procedures being performed) and ability to adhere to the study restrictions and assessments schedule.

      • Diabetic patient is defined as a patient with a documented history of type II DM or a documented history of a fasting glucose > 200mg/dl or 11.0 mmol/l or 2x fasting glucose > 126 mg/dl or 6.9 mmol/l (2x =recorded twice).

Exclusion Criteria:

  • Subjects will not be considered eligible for entry in the study if they meet one or more of the following criteria.

    1. Medical history, physical examination, vital signs, clinical laboratory tests, 12-lead ECG and Chest X ray (to exclude tuberculosis in India only) with any significant abnormalities, in the opinion of the investigator.
    2. Subjects with any known somatic illness, including neoplasm, endocrine disorder such as cushing’s disease, PCOD and uncontrolled hypothyroidism, neurologic disorder, active infection, or recent surgical procedure within 3 months of the study initiation.
    3. Subject currently using medication, which can influence glucose or FFA metabolism such as fibrates, niacin, ACE inhibitors, PPAR agonists, omega 3 fatty acids.
    4. eGFR < 60 mL/min/1.73m2 at screening as evaluated by Modification of Diet in Renal Disease (MDRD) method.
    5. History of angina, Myocardial Infarction (MI) or stroke since last 6 months.
    6. Hypertension with SBP/DBP ≥160/100 mmHg at screening.
    7. ALT or AST ≥ ULN*3 at screening
    8. History or presence of malignancy.
    9. History of recreational drug use within the last 30 days, or regular consumption of greater than 2 units of alcohol/day.
    10. History of allergy to the test drug or any drug chemically similar to the drug under investigation.
    11. Seropositive for Hepatitis B, Hepatitis C or HIV.
    12. Subjects suffering from any psychiatric (acute or chronic) illness.
    13. Intake of any medication except those permitted in this study (see Section 6.6).
    14. Intake of any investigational drug in the period within 3 months prior to the first dose of study drug.
    15. History of significant blood loss due to any reason, including blood donation, in the 12 weeks prior to the first dose of study drug; or the total blood loss in the last 3 months, including for this study, exceeds 450 mL.
    16. History of any bleeding disorder.
    17. Existence of any surgical or medical condition which, in the judgment of the principal investigator, might interfere with the absorption, distribution, metabolism or excretion of the study drug or might be likely to compromise the safety of the subject.
    18. Inability to communicate or co-operate with the investigator because of language problems, poor mental development or impaired cerebral function.
    19. Inability to comply with study requirements.
    20. Positive drugs of abuse test (at screening) and alcohol breath test.
    21. Heavy smokers (who are smoking >15 cigarettes or equivalent per day).
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01408667

Contact: Purav Thakkar, MBBS 91-79-23969100 ext 196 puravthakkar@torrentpharma.com
Contact: KumarPrafull Chandra, MD 91-79-23969100 ext 193 kumarprafullchandra@torrentpharma.com

Academic Medical Centre,
Amsterdam, Netherlands, 1100 DD
Sponsors and Collaborators
Torrent Pharmaceuticals Limited
Principal Investigator: Erik Stroes, MD, PhD Department of Vascular Medicine, AMC
  More Information


Responsible Party: Torrent Pharmaceuticals Limited
ClinicalTrials.gov Identifier: NCT01408667    
History of Changes
Other Study ID Numbers: CT/P015/CMR/2010/02_01, 2011-002398-42
Study First Received: July 29, 2011
Last Updated: September 14, 2011
Health Authority: Netherlands: Medical Ethics Review Committee (METC)

Keywords provided by Torrent Pharmaceuticals Limited:

insulin sensitivity
cardiometabolic risk
hyperinsulinemic euglycemic clamp

Additional relevant MeSH terms:

Metabolic Syndrome X
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on November 28, 2011

Leave a Reply

You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>




12 + six =